Long-term efficacy of vasodilating β-blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Long-term benefit of vasodilating β-blockers is unknown. This study aimed to investigate the long-term benefit of vasodilating β-blockers over conventional β-blockers in patients with acute myocardial infarction (AMI). Methods: Using nationwide prospective multicenter Korean Acute Myocardial Infarction Registry data, we analyzed 3-year clinical outcomes of 7,269 patients with AMI who received percutaneous coronary intervention (PCI) and β-blocker therapy. Patients were classified according to treatment strategy (vasodilating β-blockers vs. conventional β-blockers). The primary endpoint was a composite of cardiac death, myocardial infarction (MI), and hospitalization for heart failure (HF) at 3 years. Secondary outcomes were each component of the primary outcome. Propensity score matching was performed to adjust for differences of baseline characteristics. Results: In 3,079 pairs (6,158 patients) of propensity score-matched patients, the primary outcome occurred significantly less in the vasodilating β-blockers group compared with the conventional β-blockers group (7.6% vs. 9.8%, p = 0.003). Among the secondary outcomes, cardiac death occurred significantly less in the vasodilating β-blockers group than in the conventional group (3.5% vs. 4.8%, p = 0.015). The incidence rates of MI (2.4% vs. 3.0%, p = 0.160) or hospitalization for HF (2.6% vs. 3.2%, p = 0.192) were not significantly different between the two groups. Conclusions: Vasodilating β-blocker therapy was associated with better clinical outcomes compared with conventional β-blocker therapy in AMI patients undergoing PCI during 3 years follow-up. Vasodilating β-blockers could be recommended preferentially for these patients.
Abstract
Background/Aims: Long-term benefit of vasodilating β-blockers is unknown. This study aimed to investigate the long-term benefit of vasodilating β-blockers over conventional β-blockers in patients with acute myocardial infarction (AMI). Methods: Using nationwide prospective multicenter Korean Acute Myocardial Infarction Registry data, we analyzed 3-year clinical outcomes of 7,269 patients with AMI who received percutaneous coronary intervention (PCI) and β-blocker therapy. Patients were classified according to treatment strategy (vasodilating β-blockers vs. conventional β-blockers). The primary endpoint was a composite of cardiac death, myocardial infarction (MI), and hospitalization for heart failure (HF) at 3 years. Secondary outcomes were each component of the primary outcome. Propensity score matching was performed to adjust for differences of baseline characteristics. Results: In 3,079 pairs (6,158 patients) of propensity score-matched patients, the primary outcome occurred significantly less in the vasodilating β-blockers group compared with the conventional β-blockers group (7.6% vs. 9.8%, p = 0.003). Among the secondary outcomes, cardiac death occurred significantly less in the vasodilating β-blockers group than in the conventional group (3.5% vs. 4.8%, p = 0.015). The incidence rates of MI (2.4% vs. 3.0%, p = 0.160) or hospitalization for HF (2.6% vs. 3.2%, p = 0.192) were not significantly different between the two groups. Conclusions: Vasodilating β-blocker therapy was associated with better clinical outcomes compared with conventional β-blocker therapy in AMI patients undergoing PCI during 3 years follow-up. Vasodilating β-blockers could be recommended preferentially for these patients.
참고문헌 (28)
- Amsterdam EA, "2014 AHA", ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes : a report of the American College of Cardiology, Circulation, pp.2014, 130[DOI]
- Ibanez B, "2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)", Eur Heart J, 39, pp.119~177 (2018)
- O’Gara PT, "2013 ACCF", AHA guideline for the management of ST-elevation myocardial infarction : a report of the American College of Cardiology Foundation, Circulation, pp.2013, 127[DOI]
- Roffi M, "2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology(ESC)", Eur Heart J, 37, pp.267~315 (2016)
- Giugliano D, "Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial", Ann Intern Med, 126, pp.955~959 (1997)
- Bakris GL, "Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension : a randomized controlled trial", JAMA, 292, pp.2227~2736 (2004)
- Poirier L, "Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients", J Hypertens, 19, pp.1429~1435 (2001)
- Bank AJ, "Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus", Am J Hypertens, 20, pp.777~783 (2007)
- Stauffer BL, "Nebivolol, but not metoprolol, treatment improves endothelial fibrinolytic capacity in adults with elevated blood pressure", J Am Heart Assoc, 6, pp.e007437~ (2017)
- Feuerstein GZ, "Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection", Eur Heart J, 16(Suppl F), pp.38~42 (1995)
- McEniery CM, "Central blood pressure : current evidence and clinical importance", Eur Heart J, 35, pp.1719~1725 (2014)
- Munzel T, "Nebivolol : the somewhat-different beta-adrenergic receptor blocker", J Am Coll Cardiol, 54, pp.1491~1499 (2009)
- Chung J, "Benefit of vasodilating β-blockers in patients with acute myocardial infarction after percutaneous coronary intervention : nationwide multicenter cohort study", J Am Heart Assoc, 6, pp.e007063~ (2017)
- Chen KY, "Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention", Circulation, 119, pp.3207~3214 (2009)
- Dahlof B, "Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE) : a randomised trial against atenolol", Lancet, 359, pp.995~1003 (2002)
- Chen ZM, "Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction : randomised placebo-controlled trial", Lancet, 366, pp.1622~1632 (2005)
- Dahlof B, "Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA) : a multicenter randomised controlled trial", Lancet, 366, pp.895~906 (2005)
- Dargie HJ, "Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial", Lancet, 357, pp.138513~138590 (2001)
- Poole-Wilson PA, "Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial(COMET) : randomised controlled trial", Lancet, 362, pp.7~13 (2003)
- Ruwald MH, "Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT(multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy)", J Am Coll Cardiol, 61, pp.1518~1526 (2013)
- Fonseca VA, "Effects of beta-blockers on glucose and lipid metabolism", Curr Med Res Opin, 26, pp.615~629 (2010)
- Giugliano D, "Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension", Diabetes Care, 21, pp.631~636 (1998)
- Falciani M, "Effects of nebivolol on human platelet aggregation", J Cardiovasc Pharmacol, 38, pp.922~929 (2001)
- Lopez BL, "Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction", Pharmacology, 51, pp.165~173 (1995)
- Xiaozhen H, "Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy", Blood Press, 19, pp.40~47 (2010)
- Gullu H, "Different effects of atenolol and nebivolol on coronary flow reserve", Heart, 92, pp.1690~1691 (2006)
- van der Does R, "Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris", Am J Cardiol, 83, pp.643~649 (1999)
- Van Bortel LM, "Exercise tolerance with nebivolol and atenolol", Cardiovasc Drugs Ther, 6, pp.239~247 (1992)